Zymeworks enters its first ZymeLink antibody-drug conjugate platform licensing agreement with Iconic Therapeutics

This article was originally published here

This is the first collaboration leveraging the ZymeLink platform and represents Zymeworks’ third technology platform licensed to a collaborator. “We believe this first ZymeLink licensing deal provides further

The post Zymeworks enters its first ZymeLink antibody-drug conjugate platform licensing agreement with Iconic Therapeutics appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply